Improving Outcomes for Advanced Basal Cell Carcinoma: Case Study
Basal cell carcinoma (BCC) is the most common type of cancer, sub-divided into uncomplicated and advanced cases.
• Limited options when BCC progresses to an advanced state.
• Erivedge™ (vismodegib) was recently approved in Canada for the treatment of adult patients with histologically confirmed metastatic or locally advanced BCC where surgery or radiotherapy is not appropriate.
• We report early outcomes of 2 patients